KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBITDA Margin (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed EBITDA Margin for 16 consecutive years, with 109.95% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 9736.0% year-over-year to 109.95%, compared with a TTM value of 75.93% through Sep 2025, up 29675.0%, and an annual FY2024 reading of 270.3%, up 51910.0% over the prior year.
  • EBITDA Margin was 109.95% for Q3 2025 at TherapeuticsMD, down from 73.0% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 32264.66% in Q2 2022 and bottomed at 8182.2% in Q3 2022.
  • Average EBITDA Margin over 5 years is 344.56%, with a median of 198.24% recorded in 2021.
  • The sharpest move saw EBITDA Margin surged 3245009bps in 2022, then crashed -3281706bps in 2023.
  • Year by year, EBITDA Margin stood at 65.39% in 2021, then skyrocketed by 73bps to 113.32% in 2022, then crashed by -255bps to 175.9% in 2023, then skyrocketed by 126bps to 45.73% in 2024, then tumbled by -340bps to 109.95% in 2025.
  • Business Quant data shows EBITDA Margin for TXMD at 109.95% in Q3 2025, 73.0% in Q2 2025, and 221.63% in Q1 2025.